#Sweden #Stockholm #Moberg Pharma #Terclara #Karo Healthcare

Moberg Pharma Forms Strategic Alliance with Karo Healthcare for MOB-015/Terclara in Europe

In a significant move for the pharmaceutical landscape, Moberg Pharma AB has formalized an exclusive licensing agreement with Karo Healthcare AB to commercialize its innovative product, MOB-015 (Terclara®), across a wide swath of European markets. The partnership covers 19 countries, catering to a population of around 500 million people, including major economies like the UK and other EU nations.

This collaboration not only enhances the accessibility of MOB-015 but also accelerates the growth potential of both companies in the competitive pharmaceutical industry. Karo Healthcare will spearhead the marketing, distribution, and sales efforts, leveraging its established presence in the European health market. While the specific financial details of the agreement remain under wraps, it is known to encompass royalties and compensation related to product delivery, marking a mutually beneficial relationship.

Anna Ljung, CEO of Moberg Pharma, expressed her enthusiasm about the partnership, pointing out that Karo Healthcare's strong commercial footprint throughout Europe presents a prime opportunity to introduce MOB-015/Terclara under the reputable Lamisil® brand. This name recognition is expected to bolster the product's establishment as a market leader beyond Sweden and Norway, where Moberg Pharma has previously operated.

Similarly, Christoffer Lorenzen, the CEO of Karo, acknowledged Moberg Pharma's commitment to creating a robust, clinically validated product. He noted that marketing MOB-015/Terclara under the Lamisil® brand perfectly combines scientific advancements with commercial efficacy, positioning them advantageously in the marketplace.

Understanding MOB-015/Terclara®

MOB-015/Terclara® is heralded as the next-generation topical formulation of terbinafine, the active ingredient in the globally recognized antifungal treatment Lamisil®. Historically, oral antifungal treatments for nail fungus have posed various health risks, including drug interactions and liver complications. In contrast, MOB-015 offers a topical solution that effectively addresses these concerns. This innovative application denotes a significant step forward in addressing nail fungus effectively, as evidenced by the registration studies showing a 76% mycological cure rate among participants.

This launch is particularly noteworthy as it represents the first topical treatment that successfully matches the efficacy of oral treatments with its unique delivery mechanism, overcoming previous challenges that limited the effectiveness of topical terbinafine solutions.

Regulatory Pathways and Market Strategy

The deployment of MOB-015/Terclara under the Lamisil® brand not only optimizes its market potential but is contingent upon receiving approvals from national health authorities throughout Europe. Both Moberg Pharma and Karo Healthcare are keen to initiate this launch swiftly, adhering closely to regulatory timelines. The collaborative effort will also focus on expanding marketing approvals to additional European countries as opportunities arise, particularly in those regions where the product is already authorized.

As both companies forge ahead with their plans, it's important to note that while Karo Healthcare leads this venture in Europe, Moberg Pharma will simultaneously pursue commercial opportunities in other territories, notably the United States, as part of its overarching strategy.

In closing, this collaboration signifies a pivotal moment in Moberg Pharma’s journey towards solidifying MOB-015/Terclara® as a leading treatment for nail fungus across Europe. The partnership stands out as a model of how strategic alliances can leverage expertise and distribution power to meet market demands efficiently. Importantly, the connection to Moberg Pharma will be made transparent through marketing concepts, underscoring the company's involvement in the product's success.

Overall, this partnership not only marks a promising new chapter for Moberg Pharma but also for comprehensive healthcare access in Europe, aligning innovative treatment options with patient needs.